Virtual Poster Session in Neuroendocrine Tumors From Seattle - priME Oncology
Virtual Poster
Virtual Poster

Virtual Poster Session in Neuroendocrine Tumors From Seattle

Practical Application of Key Data Presented During the NANETS 11th Annual Multidisciplinary NET Disease Symposium

Not a member of My prIME? Join now for instant access.

View CME-certified presentations and downloadable slides covering the most up-to-date clinical trial data on neuroendocrine tumors (NETs) from the NANETS 11th Annual Multidisciplinary NET Disease Symposium.

Interactive Presentation

Interactive Presentation

Downloadable Slides

Downloadable Slides



0.75 AMA PRA Category 1 Credit

Release Date

Release Date

Oct 10, 2018

Expiration Date

Oct 10, 2019

Wasif M. Saif, MD

The sequencing of lanreotide (LAN) after octreotide LAR (OCT) for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs)

Featured Expert: Wasif M. Saif, MD

Jonathan Strosberg, MD

Clinical outcomes in patients with baseline renal dysfunction in the NETTER-1 study: 177Lu-DOTATATE vs high dose octreotide in progressive midgut neuroendocrine tumors

Featured Expert: Jonathan Strosberg, MD

N. Arvind Dasari, MD

A pilot study of the cyclin dependent kinases 4, 6 inhibitor ribociclib in patients with foregut neuroendocrine tumors

Featured Expert: N. Arvind Dasari, MD

Scott Paulson, MD

Prospective observational study in patients with locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors treated with lanreotide depot in a US community oncology setting: Interim analysis

Featured Expert: Scott Paulson, MD

  • N. Arvind Dasari, MDThe University of Texas
    MD Anderson Cancer Center
    Houston, Texas, United States
  • Scott Paulson, MDTexas Oncology
    Dallas, Texas, United States
  • Wasif M. Saif, MDTufts Medical Center
    Boston, Massachusetts, United States
  • Jonathan Strosberg, MDMoffitt Cancer Center
    Tampa, Florida, United States

This educational activity is designed for medical oncologists, endocrinologists, gastroenterologists and other healthcare providers involved and/or interested in the management of patients with neuroendocrine tumors.

After successful completion of this educational activity, participants should be able to:

  • Describe recent findings on the contemporary use of somatostatin analogue therapy in the management of gastroenteropancreatic NETs (GEP-NETs)
  • Assess clinical trial data describing treatment options for patients with neuroendocrine tumors

This educational activity is supported by a grant from Ipsen.

Continuing Education

prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

prIME Oncology designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


This activity is provided by prIME Oncology.

Disclosure Information

Method of Participation

There are no fees for participating in and receiving CME credit for this activity. In order to receive credit, participants must successfully complete the online activity evaluation. Your participation in this CME activity will be recorded in prIME Oncology’s database. However, upon request, your CME credit certificate will be emailed to you. Technical requirements may be found under the Terms of Use.

Links to the post-test are available on the video player pages.

Disclosure of Relevant Financial Relationships

prIME Oncology assesses relevant financial relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Dr Dasari has disclosed that he has no relevant financial relationships to report. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Paulson has disclosed that he has performed contracted research for Ipsen and Taiko. He has disclosed membership on advisory boards or review panels with Bristol-Myers Squibb, Eisai, and Ipsen. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Saif has disclosed that he has received honoraria for promotional speakers’ bureau(s) from Ipsen. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Strosberg has disclosed that he has received consulting fees from Ipsen and Novartis Oncology. He has also received honoraria for promotional speakers’ bureaus from Ipsen and Lexicon. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

The employees of prIME Oncology have disclosed:

  • Briana Betz, PhD (scientific content reviewer/planner) – no relevant financial relationships
  • Trudy Stoddert, ELS (editorial content reviewer) – no relevant financial relationships

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.